Atea Pharmaceuticals, Inc. (AVIR) fundamentals score
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company leveraging its deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.4 out of 10, Weak long-term fundamentals
- Growth: 1.5/10
- Profitability: 6.3/10
- Financial health: 10.0/10
- Earnings quality: 1.8/10
- Valuation: 1.5/10
Scores are calculated from Atea Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2021-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10